We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-18.55%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.33B
AUM Growth
-$894M
Cap. Flow
-$58.7M
Cap. Flow %
-2.52%
Top 10 Hldgs %
69.04%
Holding
126
New
9
Increased
16
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
NMRA icon
Neumora Therapeutics
NMRA
+$35M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
SLRN
ACELYRIN
SLRN
+$13.8M
4
IMGN
Immunogen Inc
IMGN
+$12.4M
5
SGMT icon
Sagimet Biosciences
SGMT
+$12.3M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$41.1M
2
SAGE
Sage Therapeutics
SAGE
+$23.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$15.2M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.42%
2 Consumer Discretionary 42.85%
3 Miscellaneous 1.65%
4 Technology 0.61%
5 Communication Services 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVA icon
1
CAVA Group
CAVA
$6.53B
$980M 42.04%
32,007,990
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$890M
$128M 5.49%
117,553,284
– –
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$88.2M 3.78%
2,024,226
-30,955
-2% -$1.11M
ONC
4
BeOne Medicines Ltd
ONC
$39.2B
$72.7M 3.12%
403,934
-8,562
-2% -$1.69M
RVMD icon
5
Revolution Medicines
RVMD
$43.7B
$70M 3%
2,529,737
+128,120
+5% +$3.8M
SRRK icon
6
Scholar Rock
SRRK
$6.75B
$64.3M 2.76%
9,059,507
– –
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
$63.3M 2.71%
1,664,572
+614,505
+59% +$27M
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$49.4M 2.12%
4,062,567
-500,000
-11% -$6.45M
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$49M 2.1%
2,138,188
-1,807
-0.1% -$94.8K
CYTK icon
10
Cytokinetics
CYTK
$10.3B
$44.7M 1.92%
1,518,831
+102,800
+7% +$3.42M
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
$42M 1.8%
1,816,620
– –
NMRA icon
12
Neumora Therapeutics
NMRA
$195M
$39.5M 1.7%
+2,802,702
New +$35M
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$35.8M 1.53%
1,638,858
– –
MRTX
14
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$30.5M 1.31%
700,000
+450,000
+180% +$16.1M
SLRN
15
DELISTED
ACELYRIN
SLRN
$25.1M 1.08%
2,469,279
+648,065
+36% +$13.8M
KYMR icon
16
Kymera Therapeutics
KYMR
$9.53B
$25.1M 1.08%
1,805,346
– –
SLN
17
Silence Therapeutics
SLN
$809M
$24.6M 1.05%
2,500,000
+800,000
+47% +$5.9M
IMGN
18
DELISTED
Immunogen Inc
IMGN
$24M 1.03%
1,512,113
+746,616
+98% +$12.4M
IGMS
19
DELISTED
IGM Biosciences
IGMS
$21.1M 0.9%
2,522,244
– –
KURA icon
20
Kura Oncology
KURA
$1.03B
$18.4M 0.79%
2,018,056
– –
AGEN
21
Agenus
AGEN
$312M
$17.7M 0.76%
781,562
– –
SE icon
22
Sea Limited
SE
$66.6B
$17.4M 0.75%
397,000
+47,000
+13% +$2.3M
DNLI icon
23
Denali Therapeutics
DNLI
$3.37B
$16.6M 0.71%
802,899
– –
KLRS
24
Kalaris Therapeutics
KLRS
$80.5M
$14.2M 0.61%
286,833
– –
SDGR icon
25
Schrodinger
SDGR
$1.42B
$14.1M 0.61%
500,000
-200,000
-29% -$8.06M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2023 Portfolio in Review

As of Q3 2023, Artal Group held 126 positions worth $2.33B, down 28% from $3.23B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group's Q3 2023 filing shows 9 new, 16 increased, 12 reduced and 23 closed positions. Its largest new stake was Neumora Therapeutics: 2,802,702 shares worth $39.5M. The largest sale was Krystal Biotech, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 55% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q3 2023 buy was Neumora Therapeutics: 2,802,702 shares worth $39.5M.
  • Artal Group added most to Apellis Pharmaceuticals in Q3 2023, an estimated $27M increase.
  • Artal Group's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $8.06M.
  • Artal Group fully exited Krystal Biotech in Q3 2023, selling an estimated $41.1M.
  • Artal Group's ten largest holdings make up 69% of its $2.33B portfolio in Q3 2023.
  • Artal Group opened 9 new positions and closed 23 in Q3 2023.
  • Artal Group's portfolio value fell 28% quarter-over-quarter to $2.33B.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.